Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome

International Journal of Cardiology

Volumn 240, Issue , 2017, Pages 332-338

  Yamada, Yuichiro ^a   Takeuchi, Shino ^b   Yoneda, Mamoru ^a   Ito, Shogo ^a   Sano, Yusuke ^a   Nagasawa, Kai ^a   Matsuura, Natsumi ^a   Uchinaka, Ayako ^a   Murohara, Toyoaki ^a   Nagata, Kohzo ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

AMP activated protein kinase; Atorvastatin; Inflammation; Metabolic syndrome; Nuclear factor B

Indexed keywords

ADIPONECTIN; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; S6 KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR RELA; AUTACOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDITIS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART MUSCLE FIBROSIS; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; CELL CULTURE; DAHL RAT; DRUG EFFECTS; INFLAMMATION; METABOLISM; OBESITY; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION;

ADIPOSE TISSUE; ANIMALS; ATORVASTATIN CALCIUM; CELLS, CULTURED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; METABOLIC SYNDROME; MYOCYTES, CARDIAC; OBESITY; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, INBRED DAHL;

EID: 85019168137     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.04.103     Document Type: Article

References (45)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
2. Shepherd, J., Cobbe, S.M., Ford, I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333 (1995), 1301–1307.
3. Ichihara, S., Noda, A., Nagata, K., et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc. Res. 69 (2006), 726–735.
4. Saka, M., Obata, K., Ichihara, S., et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J. Cardiovasc. Pharmacol. 47 (2006), 770–779.
5. Forrester, J.S., Libby, P., The inflammation hypothesis and its potential relevance to statin therapy. Am. J. Cardiol. 99 (2007), 732–738.
6. Sun, W., Lee, T.S., Zhu, M., et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 114 (2006), 2655–2662.
7. Kureishi, Y., Luo, Z., Shiojima, I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6 (2000), 1004–1010.
8. Salminen, A., Hyttinen, J.M., Kaarniranta, K., AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. (Berl.) 89 (2011), 667–676.
9. Brault, M., Ray, J., Gomez, Y.H., Mantzoros, C.S., Daskalopoulou, S.S., Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 63 (2014), 735–745.
10. Wong, V., Stavar, L., Szeto, L., et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 184 (2006), 348–355.
11. Chen, Y., Ohmori, K., Mizukawa, M., et al. Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ. J. 71 (2007), 144–152.
12. Furuya, D.T., Poletto, A.C., Favaro, R.R., Martins, J.O., Zorn, T.M., Machado, U.F., Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice. Metabolism 59 (2010), 395–399.
13. fa rat. Nutr. Diabetes, 1, 2011, e1.
14. fa rats: a new animal model of metabolic syndrome. Hypertens. Res. 35 (2012), 186–193.
15. Matsuura, N., Nagasawa, K., Minagawa, Y., et al. Restraint stress exacerbates cardiac and adipose tissue pathology via beta-adrenergic signaling in rats with metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 308 (2015), H1275–H1286.
16. Nagasawa, K., Matsuura, N., Takeshita, Y., et al. Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486. Nutr. Diabetes., 6, 2016, e207.
17. Takeshita, Y., Watanabe, S., Hattori, T., et al. Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome. Hypertens. Res. 38 (2015), 741–750.
18. Nagata, K., Somura, F., Obata, K., et al. AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. Hypertension 40 (2002), 168–174.
19. Yamada, Y., Tsuboi, K., Hattori, T., et al. Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension. Hypertens. Res. 34 (2011), 809–816.
20. Hattori, T., Murase, T., Takatsu, M., et al. Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome. J. Am. Heart Assoc., 3, 2014, e001312.
21. Sales, C.H., Santos, A.R., Cintra, D.E., Colli, C., Magnesium-deficient high-fat diet: effects on adiposity, lipid profile and insulin sensitivity in growing rats. Clin. Nutr. 33 (2014), 879–888.
22. Elmarakby, A.A., Loomis, E.D., Pollock, J.S., Pollock, D.M., NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension 45 (2005), 283–287.
23. fa rats as a new animal model of metabolic syndrome. Nagoya J. Med. Sci. 76 (2014), 35–49.
24. Takatsu, M., Nakashima, C., Takahashi, K., et al. Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. Hypertension 62 (2013), 957–965.
25. Nagata, K., Obata, K., Xu, J., et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 (2006), 656–664.
26. fa rats as a new animal model of metabolic syndrome. Hypertension 59 (2012), 694–704.
27. Ito, S., Sano, Y., Nagasawa, K., et al. Highly purified eicosapentaenoic acid ameliorates cardiac injury and adipose tissue inflammation in a rat model of metabolic syndrome. Obes. Sci. Pract. 2 (2016), 318–329.
28. Baker, R.G., Hayden, M.S., Ghosh, S., NF-kappaB, inflammation, and metabolic disease. Cell Metab. 13 (2011), 11–22.
29. Surh, Y.J., Kundu, J.K., Na, H.K., Lee, J.S., Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J. Nutr. 135 (2005), 2993s–3001s.
30. Choi, H.C., Song, P., Xie, Z., et al. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J. Biol. Chem. 283 (2008), 20186–20197.
31. Kou, R., Sartoretto, J., Michel, T., Regulation of Rac1 by simvastatin in endothelial cells: differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-beta. J. Biol. Chem. 284 (2009), 14734–14743.
32. Suganami, T., Tanimoto-Koyama, K., Nishida, J., et al. Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 84–91.
33. Gao, Z., Zhang, J., Henagan, T.M., et al. P65 inactivation in adipocytes and macrophages attenuates adipose inflammatory response in lean but not in obese mice. Am. J. Physiol. Endocrinol. Metab. 308 (2015), E496–E505.
34. Freedland, E.S., Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr. Metab. (Lond.), 1, 2004, 12.
35. Planavila, A., Laguna, J.C., Vazquez-Carrera, M., Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim. Biophys. Acta 1687 (2005), 76–83.
36. Youssef, S., Stuve, O., Patarroyo, J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002), 78–84.
37. van Harmelen, V., Skurk, T., Rohrig, K., Hauner, H., HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes. Horm. Metab. Res. 35 (2003), 466–470.
38. Ferre, P., Foufelle, F., SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm. Res. 68 (2007), 72–82.
39. Kim, J.B., Spiegelman, B.M., ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10 (1996), 1096–1107.
40. Han, L., Li, M., Liu, Y., Han, C., Ye, P., Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats. Pharmacology 89 (2012), 74–82.
41. Matsuura, N., Asano, C., Nagasawa, K., et al. Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. Int. J. Cardiol. 179 (2015), 360–369.
42. Dyck, J.R., The ischemic heart: starving to stimulate the adiponectin-AMPK signaling axis. Circulation 116 (2007), 2779–2781.
43. Matsuda, K., Fujishima, Y., Maeda, N., et al. Positive feedback regulation between adiponectin and T-cadherin impacts adiponectin levels in tissue and plasma of male mice. Endocrinology 156 (2015), 934–946.
44. Haruta, T., Uno, T., Kawahara, J., et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol. 14 (2000), 783–794.
45. Inoki, K., Zhu, T., Guan, K.L., TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003), 577–590.